[ad_1]
Editor’s Be aware: This roundup is supposed to focus on a few of the most notable funding rounds of the month and isn’t supposed to be complete.
Well being tech firms made a number of main funding bulletins in November. Here’s a checklist of a few of the greatest funding rounds.
Perform Well being raises $298 million in Sequence B funding
Austin, Texas-based Perform Well being is a platform that offers customers entry to greater than 160 completely different lab checks, together with for hormones, coronary heart well being, immunity and metabolism. An annual subscription to the platform prices $365.
Its Sequence B spherical was led by Redpoint Ventures. Different buyers embrace Nat Friedman and Daniel Gross’ NFDG, a16z, Aglaé Ventures and Alumni Ventures. In complete, the corporate has raised $350 million and it now has a valuation of $2.5 billion.
Hippocratic AI secures $126 million in Sequence C funding
Palo Alto, California-based Hippocratic AI builds non-diagnostic patient-facing AI brokers. Its brokers assist with duties like appointment scheduling, affected person consumption historical past, eligibility and profit confirmations and extra.
Its Sequence C spherical was led by Avenir Development and included participation from CapitalG, Basic Catalyst, Andreessen Horowitz (a16z), Kleiner Perkins, Premji Make investments and Common Well being Providers. The corporate has raised $404 million thus far and is now valued at $3.5 billion. The funding will assist the corporate deepen its buyer deployments, spend money on product growth and pursue mergers and acquisitions.
Tala Well being pulls $100 million
Tala Well being, based mostly in San Francisco, is a enterprise of holding firm Titan Holdings. Tala helps clinicians by deploying AI brokers “throughout the total affected person journey.” Sufferers can entry Tala Well being’s companies 24/7 via its digital care platform and get referred to clinicians when wanted.
The corporate’s funding was led by Sofreh Capital. The financing will assist “develop its AI and medical groups, speed up product growth, and develop partnerships with main healthcare establishments to deliver its AI-powered platform to extra sufferers and suppliers throughout the U.S.,” in keeping with the announcement.
Beacon Biosignals raises $86 million in Sequence B funding
Boston-based Beacon Biosignals gives FDA-cleared wearable EEG know-how and AI to investigate neural information to assist breakthroughs in neurology, psychiatry and sleep drugs. Its Waveband system, for instance, measures the mind’s electrical exercise throughout sleep and whereas awake. It really works with clinicians and biopharma companions to advance analysis, enhance diagnostics and develop new therapies.
The funding was from Innoviva, Google Ventures (GV), Nexus NeuroTech Ventures, S32, Catalio Capital Administration, Takeda, Basic Catalyst, Logos Capital, Casdin Capital and Indicator Ventures. In complete, Beacon has raised $121 million. With the funding, the corporate will scale its know-how and operations to “speed up neurobiomarker discovery and broaden medical adoption,” the announcement acknowledged.
Picture: Abscent84, Getty Photographs
[ad_2]
